Bio tech company updates — 11/12/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
South Korea’s government pledged increased strategic investment in biotechnology to reduce reliance on foreign technologies, framing the global competition as a "war without gunfire." Meanwhile, South Korean biotech firms are actively seeking partnerships at BIO-Europe 2026 in Cologne, with companies like Bioneer and Alteogen pitching cancer and obesity treatments to global pharmaceutical giants.
Key Findings
- Government Policy Shift: The Korean government announced plans to increase strategic investment in biotechnology and strengthen industry cooperation to ensure technological sovereignty.
- BIO-Europe 2026 Participation: South Korean biotech firms, including Bioneer, Alteogen, D&D Pharmatech, and Ligachem Biosciences, are attending BIO-Europe 2026 in Cologne to pursue licensing and partnership deals for obesity, cancer, and liver disease treatments.
- Specific Product Interest: Bioneer reported significant interest from global drugmakers in its SAMiRNA-based hair loss treatments during the event.
- Scale of Event: More than 3,200 companies from over 60 countries are participating in BIO-Europe 2026, which runs until November 11.
- Policy Forum: The Ministry of Science and ICT hosted the 2026 Bio Future Forum on November 11 to set new bio policy agendas.
Details
Government Pledges Strategic Biotech Investment
In a move to strengthen technological sovereignty, South Korea has pledged to increase strategic investment in the biotechnology sector. Officials described the global race for biotech leadership as a “war without gunfire,” emphasizing the need to reduce reliance on foreign technologies. This announcement aligns with the Ministry of Science and ICT’s hosting of the 2026 Bio Future Forum on November 11, where new bio policy agendas were established.
Korean Biotechs Seek Global Partnerships at BIO-Europe
South Korean pharmaceutical and biotech companies are heavily represented at BIO-Europe 2026 in Cologne, Germany. The event, which concludes on November 11, serves as a critical hub for licensing and joint development negotiations.
Key participants include:
- Bioneer: The firm highlighted its SAMiRNA-based hair loss treatments, which have drawn interest from global drugmakers.
- Alteogen, D&D Pharmatech, Ligachem Biosciences, ABL Bio, and G2Gbio: These companies are pitching obesity and cancer drug candidates to potential partners.
- General Overview: Other Korean firms are showcasing cancer treatments, liver disease drugs, and drug-delivery technologies, aiming to secure financing for development and access to overseas markets.
The scale of the event is substantial, with over 3,200 companies from more than 60 countries in attendance, underscoring the competitive environment Korean firms face as they seek to expand their global footprint.
Sources
Korean Biotechs Head to BIO-Europe to Pitch Obesity, Cancer Drugs - Seoul Economic Daily
Korean biotechs pitch drug candidates at BIO-Europe | Aju Press
Market Calendar for November 10: Samsung Biologics Rights Offering - Seoul Economic Daily
Korea
Hanmi, Samsung Securities Team Up to Back Biotech Startups - Seoul Economic Daily
koreabiomed.com
dongascience.com
en.sedaily.com
ajupress.com
en.sedaily.com
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
